{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:18:23Z","timestamp":1777004303878,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to determine the risk factors that may be associated with colistin-induced acute kidney injury (AKI) to promote the safer use of colistin in the treatment of nosocomial infections caused by multidrug-resistant Gram-negative bacteria in intensive care units.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective observational study was conducted among adult patients who received a minimum of 48\u00a0h of intravenous colistin from January 2020 to December 2020 at the intensive care unit of a tertiary care hospital. AKI diagnosis and staging were made based on the Kidney Disease Improving Global Outcome Criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 148 patients who received intravenous colistin at a daily dose of 9\u00a0million IU, 54 (36%) developed AKI. In the univariate analysis, age, Charlson comorbidity index, APACHE II score, duration of colistin treatment, basal creatinine level, use of vasopressors, and vancomycin were significantly associated with AKI (p\u2009&lt;\u20090.05). The multivariate analysis revealed that the independent predictor of AKI was the use of vasopressors (OR: 3.14; 95% confidence interval: 1.39\u201397.07; p\u2009=\u20090.06).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of vasopressors in critically ill patients was independently associated with AKI developing during colistin treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03334-8","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T13:02:20Z","timestamp":1697202140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Nephrotoxicity caused by colistin use in ICU: a single centre experience"],"prefix":"10.1186","volume":"24","author":[{"given":"Isa","family":"Kilic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yavuz","family":"Ayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lkay","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u0131nar Kucukdemirci","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulbahar","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"6","key":"3334_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2217\/fmb.13.39","volume":"8","author":"T Velkov","year":"2013","unstructured":"Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an \u2018old\u2019 class of antibiotics. Future Microbiol. 2013;8(6):711\u201324. https:\/\/doi.org\/10.2217\/fmb.13.39.","journal-title":"Future Microbiol"},{"issue":"3","key":"3334_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00006-08","volume":"21","author":"D Landman","year":"2008","unstructured":"Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449\u201365. https:\/\/doi.org\/10.1128\/CMR.00006-08.","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"3334_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10\u00d7\u201820 progress\u2014development of new drugs active against gram-negative bacilli: an update from the infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685\u201394. https:\/\/doi.org\/10.1093\/cid\/cit152.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3334_CR4","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/cid\/cit453","volume":"57","author":"DS Akajagbor","year":"2013","unstructured":"Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57(9):1300\u20133. https:\/\/doi.org\/10.1093\/cid\/cit453.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3334_CR5","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1128\/AAC.01707-09","volume":"54","author":"CA Deryke","year":"2010","unstructured":"Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503\u20135. https:\/\/doi.org\/10.1128\/AAC.01707-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3334_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3906\/sag-1604-60","volume":"47","author":"H \u00d6zkaraka\u015f","year":"2017","unstructured":"\u00d6zkaraka\u015f H, K\u00f6se I, Zincircio\u011flu \u00c7, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients. Turk J Med Sci. 2017;47(4):1165\u201372. https:\/\/doi.org\/10.3906\/sag-1604-60. Published 2017 Aug 23.","journal-title":"Turk J Med Sci"},{"key":"3334_CR7","doi-asserted-by":"publisher","first-page":"e13184","DOI":"10.7717\/peerj.13184","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Weng J, Yang J, Zhou X, Xu Z, Hou R, Zhou Z, Wang L, Chen C, Jin S. Acute kidney injury-attributable mortality in critically ill patients with sepsis. PeerJ. 2022;10:e13184. https:\/\/doi.org\/10.7717\/peerj.13184. PMID: 35356476; PMCID: PMC8958971.","journal-title":"PeerJ"},{"issue":"1","key":"3334_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), infectious Diseases Society of America (IDSA), International Society for anti-infective pharmacology (ISAP), society of critical Care Medicine (SCCM), and Society of Infectious Diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"3334_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17(1):204. https:\/\/doi.org\/10.1186\/cc11454.","journal-title":"Crit Care"},{"issue":"9","key":"3334_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Published Correction Appears in Am J Infect Control. 2008;36(9):655. https:\/\/doi.org\/10.1016\/j.ajic.2008.03.002.","journal-title":"Published Correction Appears in Am J Infect Control"},{"issue":"6","key":"3334_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","volume":"22","author":"RL Nation","year":"2009","unstructured":"Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535\u201343. https:\/\/doi.org\/10.1097\/QCO.0b013e328332e672.","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"3334_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/cid\/civ717","volume":"61","author":"L Dalfino","year":"2015","unstructured":"Dalfino L, Puntillo F, Ondok MJ, et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015;61(12):1771\u20137. https:\/\/doi.org\/10.1093\/cid\/civ717.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3334_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1128\/AAC.00871-13","volume":"58","author":"N Petrosillo","year":"2014","unstructured":"Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58(2):851\u20138. https:\/\/doi.org\/10.1128\/AAC.00871-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"3334_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","volume":"36","author":"RP Dellinger","year":"2008","unstructured":"Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 2008;36:296\u2013327.","journal-title":"Care Med"},{"key":"3334_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.kint.2016.02.017","volume":"90","author":"YR Lankadeva","year":"2016","unstructured":"Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. Kidney Int. 2016;90:100\u20138.","journal-title":"Kidney Int"},{"key":"3334_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/vec.12297","volume":"25","author":"I Keir","year":"2015","unstructured":"Keir I, Kellum JA. Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. J Veter Emerg Crit Care. 2015;25:200\u20139.","journal-title":"J Veter Emerg Crit Care"},{"key":"3334_CR17","first-page":"520","volume":"39","author":"SC Ray","year":"2019","unstructured":"Ray SC, Mason J, O\u2019Connor PM. Ischemic renal injury: can renal anatomy and associated vascular congestion explain why the medulla and not the cortex is where the trouble starts? Semin. Nephrol. 2019;39:520\u20139.","journal-title":"Nephrol"},{"issue":"1","key":"3334_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00134-009-1687-x","volume":"36","author":"AC Gordon","year":"2010","unstructured":"Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 2010;36(1):83\u201391. https:\/\/doi.org\/10.1007\/s00134-009-1687-x.","journal-title":"Intensive Care Med"},{"issue":"5","key":"3334_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4103\/ijn.IJN_130_20","volume":"31","author":"BK Prasannan","year":"2021","unstructured":"Prasannan BK, Mukthar FC, Unni VN, Mohan S, Vinodkumar K. Colistin nephrotoxicity-age and baseline kidney functions hold the key. Indian J Nephrol. 2021;31(5):449\u201353. https:\/\/doi.org\/10.4103\/ijn.IJN_130_20.","journal-title":"Indian J Nephrol"},{"issue":"4","key":"3334_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/jcm12041373","volume":"12","author":"L Al-Husinat","year":"2023","unstructured":"Al-Husinat L, Alsabbah A, Hmaid AA, et al. Norepinephrine may exacerbate septic acute kidney injury: a narrative review. J Clin Med. 2023;12(4):1373. https:\/\/doi.org\/10.3390\/jcm12041373.","journal-title":"J Clin Med"},{"issue":"12","key":"3334_CR21","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1086\/599225","volume":"48","author":"JD Hartzell","year":"2009","unstructured":"Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724\u20138. https:\/\/doi.org\/10.1086\/599225.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3334_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/cid\/cir611","volume":"53","author":"JM Pogue","year":"2011","unstructured":"Pogue JM, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879\u201384. https:\/\/doi.org\/10.1093\/cid\/cir611.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3334_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.06980717","volume":"13","author":"TA Miano","year":"2018","unstructured":"Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S. Attributable risk and time course of colistin-associated acute kidney injury. Clin J Am Soc Nephrol. 2018;13(4):542\u201350. https:\/\/doi.org\/10.2215\/CJN.06980717.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3334_CR24","doi-asserted-by":"publisher","first-page":"1067548","DOI":"10.3389\/fmed.2022.1067548","volume":"9","author":"X Lu","year":"2022","unstructured":"Lu X, Zhong C, Liu Y, et al. Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections. Front Med (Lausanne). 2022;9:1067548. https:\/\/doi.org\/10.3389\/fmed.2022.1067548. Published 2022 Dec 29.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"3334_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1023\/a:1014484101427","volume":"32","author":"M Jerki\u0107","year":"2001","unstructured":"Jerki\u0107 M, Vojvodi\u0107 S, L\u00f3pez-Novoa JM. The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction. Int Urol Nephrol. 2001;32(4):539\u201347. https:\/\/doi.org\/10.1023\/a:1014484101427.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"3334_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/KI.2013.153","volume":"84","author":"AJP Lewington","year":"2013","unstructured":"Lewington AJP, Cerd\u00e1 J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013;84(3):457\u201367. https:\/\/doi.org\/10.1038\/KI.2013.153.","journal-title":"Kidney Int"},{"issue":"5","key":"3334_CR27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1213\/ANE.0000000000000425","volume":"119","author":"M Kim","year":"2014","unstructured":"Kim M, Brady JE, Li G. Variations in the risk of acute kidney injury across intraabdominal surgery procedures. Anesth Analg. 2014;119(5):1121\u201332. https:\/\/doi.org\/10.1213\/ANE.0000000000000425.","journal-title":"Anesth Analg"},{"issue":"6","key":"3334_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107\u201315. https:\/\/doi.org\/10.1016\/j.clinthera.2007.06.014.","journal-title":"Clin Ther"},{"issue":"3","key":"3334_CR29","doi-asserted-by":"publisher","first-page":"e0173286","DOI":"10.1371\/journal.pone.0173286","volume":"12","author":"RK Shields","year":"2017","unstructured":"Shields RK, Anand R, Clarke LG, et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS ONE. 2017;12(3):e0173286. https:\/\/doi.org\/10.1371\/journal.pone.0173286. Published 2017 Mar 7.","journal-title":"PLoS ONE"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03334-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:18:36Z","timestamp":1700493516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3334"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03334-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2655286\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"4 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by Bursa City Hospital Ethics Committee (22.09.2021, 2021-17\/2). Informed consent obtained from all subjects. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}